India Stays Exclusive Marketing Rights For Eli Lilly's Cialis

Law360, New York (September 9, 2004, 12:00 AM EDT) -- The Indian patent office has stayed the exclusive marketing rights (EMR) for Eli Lilly’s anti-impotence drug Cialis, raising fresh doubts about the system that was meant as a temporary measure to phase in product patents in India.

Following a recent Calcutta High Court order, the Patent Controller sent a letter to the Drug Controller General of India communicating that the EMR granted to Eli Lilly has been stayed, the Hindu newspaper reported.

The Calcutta High Court's order in late August came following a petition filed by...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.